Advances in Down Syndrome

Area of Science:

• Genetics and Developmental Biology
• Pediatrics
• Medical Genetics

Background:

• Trisomy 21 (T21), also known as Down syndrome, is the most frequent chromosomal abnormality globally.
• It is the primary genetic cause of intellectual disability, affecting development and leading to various health issues.
• Individuals with T21 experience characteristic facial features and defects in cardiovascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, and immunologic systems.

Purpose of the Study:

• To review recent advancements in the diagnosis, prevention, and treatment of Trisomy 21 over the past decade.
• To highlight improvements in managing T21-associated complications across multiple organ systems.
• To assess the impact of these advancements on the lifespan and quality of life for individuals with T21.

Main Methods:

• A comprehensive literature review of studies published in the last 10 years focusing on Trisomy 21 management.
• Analysis of new findings and therapeutic strategies for T21-related conditions.
• Synthesis of data on diagnostic tools, preventive measures, and treatment protocols.

Main Results:

• Significant progress has been made in early diagnosis and screening for Trisomy 21.
• Novel therapeutic approaches and improved management strategies for T21-associated comorbidities have been developed.
• These advancements have contributed to a notable increase in the life expectancy and overall well-being of children with T21.

Conclusions:

• The last decade has seen substantial improvements in the comprehensive care of individuals with Trisomy 21.
• Enhanced management strategies have positively impacted health outcomes, leading to longer and better lives.
• Continued research and clinical application of new findings are crucial for further optimizing T21 care.